Compositions and methods for treating hcv

Abstract

This disclosure is directed to pharmaceutical compositions that comprise two or more therapeutic agents that, inter alia, are useful for inhibiting hepatitis C virus (HCV) and methods for inhibiting HCV by co-administering two or more anti-HCV therapeutic agents.

We claim: 
     
         1 . A combination or pharmaceutical composition comprising an amount of therapeutic agent A and an amount of therapeutic agent B, wherein therapeutic agent A is compound A or a salt thereof: 
       
         
           
           
               
               
           
         
       
       and wherein therapeutic agent B is compound B or a salt thereof: 
       
         
           
           
               
               
           
         
       
     
     
         2 . The combination or composition of  claim 1 , wherein the amount of therapeutic agent A is about 25 mg. 
     
     
         3 . The combination or composition of  claim 1 , wherein therapeutic agent B is a sodium salt of compound B. 
     
     
         4 . The combination or composition of  claim 1 , wherein the amount of therapeutic agent B is from about 400 to about 800 mg. 
     
     
         5 . The combination or composition of  claim 1 , wherein the amount of therapeutic agent A and the amount of therapeutic agent B together constitute a therapeutically effective amount. 
     
     
         6 . The combination or composition of  claim 1 , wherein the composition further comprises one or more additional therapeutic agents. 
     
     
         7 . The combination or composition of  claim 6 , wherein the additional therapeutic agent is independently selected from the group consisting of ribavirin, taribavirin, and HCV inhibitor. 
     
     
         8 . The combination or composition of  claim 6 , wherein the one or more additional therapeutic agents include an HCV protease inhibitor. 
     
     
         9 . The combination or composition of  claim 8 , wherein the one or more additional therapeutic agents include a cytochrome P-450 inhibitor. 
     
     
         10 . The combination or composition of  claim 9 , wherein the cytochrome P-450 inhibitor is ritonavir. 
     
     
         11 . The combination or composition of  claim 6 , wherein the amount of therapeutic agent A, the amount of therapeutic agent B ant the amount of the additional therapeutic agent together constitute a therapeutically effective amount. 
     
     
         12 . A pharmaceutical composition comprising an amount of therapeutic agent A and an amount of therapeutic agent B,
 wherein therapeutic agent A is compound A or a salt thereof:   
       
         
           
           
               
               
           
         
         wherein therapeutic agent B is compound B or a salt thereof: 
       
       
         
           
           
               
               
           
         
          and 
         wherein the ratio of therapeutic agent A to therapeutic agent B is about 1:20 to about 1:2000. 
       
     
     
         13 . The pharmaceutical composition of  claim 12 , wherein the amount of therapeutic agent B is about 200 mg. 
     
     
         14 . The pharmaceutical composition of  claim 12 , wherein the amount of therapeutic agent A is from about 5 mg to about 200 mg. 
     
     
         15 . The pharmaceutical composition of  claim 12 , wherein the composition further comprises one or more additional therapeutic agents 
     
     
         16 . The pharmaceutical composition of  claim 15 , wherein the one or more additional therapeutic agents include an HCV protease inhibitor. 
     
     
         17 . The pharmaceutical composition of  claim 16 , wherein the one or more additional therapeutic agents include a cytochrome P-450 inhibitor. 
     
     
         18 . The pharmaceutical composition of  claim 12 , further comprising an HCV protease inhibitor and a cytochrome P-450 inhibitor. 
     
     
         19 . The pharmaceutical composition of  claim 18 , wherein the cytochrome P-450 inhibitor is ritonavir. 
     
     
         20 . The pharmaceutical composition of  claim 12 , wherein therapeutic agent B is a sodium salt of compound B.